Education
About Us
Working with TipRanks
Follow Us
Fortrea Holdings Inc. (FTRE)
NASDAQ:FTRE
FTRE Stock Chart & Stats
$10.38
-$0.82(-4.27%)
At close: 4:00 PM EST
$10.38
-$0.82(-4.27%)
Day’s Range― - ―
52-Week Range$3.97 - $18.67
Previous CloseN/A
Volume188.47K
Average Volume (3M)1.76M
Market Cap
$979.88M
Enterprise Value$852.51M
Total Cash (Recent Filing)$174.60M
Total Debt (Recent Filing)$68.00M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 18, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding93,500,000
10 Day Avg. Volume2,126,755
30 Day Avg. Volume1,759,946
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue0.31
Enterprise Value/Gross Profit1.91
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$15.22Price Target Upside46.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.7
Revenue Forecast (FY)$2.66B
Bulls Say, Bears Say
Bulls Say
Demand Recovery And BookingsNet bookings outpaced shipments and analysts note early signs of improving biopharma demand, suggesting revenue growth could accelerate if industry funding strengthens.
Leadership And Strategic ExecutionNew leadership and a refreshed strategic plan have improved operational execution and accountability, which could drive stronger revenue performance and faster deleveraging.
Profitability And Cost SavingsAdjusted profitability exceeded expectations as full-year cost savings surpassed targets, supporting improved operating leverage and potential margin expansion.
Bears Say
Cyclicality And Pricing RiskExposure to a cyclical biopharma recovery and the possibility of renewed drug-pricing pressure raises the risk that demand improvements may reverse and hurt future revenue.
Guidance ShortfallNear-term revenue guidance was lighter than analyst expectations, creating uncertainty about growth prospects until guidance aligns with consensus.
Market Sentiment And Disruption ConcernsShare-price decline driven by fears of AI-related disruption, which some analysts view as overstated, could leave the stock vulnerable to continued sentiment-driven volatility.
Fortrea Holdings Inc. News
FTRE FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $3.97 and its highest was $18.67 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $979.88M.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is May 18, 2026 which is in 74 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on Feb 26, 2026. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.169 by -$0.079.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 0.08.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 93,500,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $0.09 in its last earnings report, missing expectations of $0.169. Following the earnings report the stock price went up 4.449%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in FTRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.22 (46.63% Upside)
$15.22 (46.63% Upside)
Blogger Sentiment
Bullish
FTRE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Bearish
Bullish news 20%
Bearish news 80%
Bearish news 80%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.96%
12-Months-Change
Fundamentals
Return on Equity
-102.41%
Trailing 12-Months
Asset Growth
-24.13%
Trailing 12-Months
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
FTRE Company Deck
FTRE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced measurable operational and financial progress (positive cash generation in Q4, exceeded cost-savings targets, debt paydown, improved DSO, backlog and book-to-bill stabilization, AI investments and commercial wins) against persistent near-term revenue headwinds (Q4 revenue decline, FSP/pass-through variability, and 2026 revenue guidance implying a YoY decline). Management reiterated a multi‑pillar turnaround approach and provided a constructive outlook for improving EBITDA and cash flow across 2026, while cautioning the recovery may be uneven in the first half. Overall, the call reflected cautious optimism with concrete execution on cost and cash metrics but continued top-line risks that make recovery incremental.View all FTRE earnings summariesFTRE Stock 12 Month Forecast
Average Price Target
$15.22
▲(46.63% Upside)
Technical Analysis
Nektar Therapeutics
―
Fulcrum Therapeutics
―
Compass Therapeutics
―
Erasca
―
Aura Biosciences Inc
―
Ownership Overview
0.53% Insiders
19.65% Mutual Funds
7.05% Other Institutional Investors
38.94% Public Companies and
Individual Investors